Presence of a High Amount of Stroma and Downregulation of SMAD4 Predict for Worse Survival for Stage I–II Colon Cancer Patients

Background: For stage I–II colon cancer a significant number (5–25%) of patients has recurrent disease within 5 years. There is need to identify these high-risk patients as they might benefit from additional treatment.

Bibliographic Details
Main Authors: Wilma E. Mesker, Gerrit-Jan Liefers, Jan M. C. Junggeburt, Gabi W. van Pelt, Paola Alberici, Peter J. K. Kuppen, Noel F. Miranda, Karin A. M. van Leeuwen, Hans Morreau, Karoly Szuhai, Rob A. E. M. Tollenaar, Hans J. Tanke
Format: Article
Language:English
Published: Hindawi Limited 2009-01-01
Series:Cellular Oncology
Online Access:http://dx.doi.org/10.3233/CLO-2009-0478

Similar Items